Table 1.

Targeting BAFF/APRIL biologics in IgAN, LN, pMN.

BAFF/APRIL-targeted	Biologics	Disease	Trial registration number	Number of participants	Status	Phase	Reference
BAFF	Blisibimod	IgAN	NCT02062684	57	Completed	Phase 2/3	(61)
	Belimumab	LN	NCT01639339	448	Completed	Phase 3	(87)
			NCT02260934	43	Completed	Phase 2	(88)
		pMN	NCT01610492	14	Completed	Phase 2	(29)
			NCT03949855	58	Recruiting	Phase 2	(102)
APRIL	Sibeprenlimab	IgAN	NCT03719443	51	Completed	Phase 1	(64)
			NCT04287985	155	Completed	Phase 2	(65)
			NCT05248646	530	Active, not recruiting	Phase 3	(60)
	Zigakibart		NCT03945318	103	Completed	Phase 1/2	(66)
			NCT05852938	383	Active, not recruiting	Phase 3	(67)
BAFF/APRIL	Telitacicept	IgAN	NCT05799287	318	Active, not recruiting	Phase 3	(69)
			NCT04291781	44	Completed	Phase 2	(70)
		LN	NCT05680480	120	Recruiting	Phase 2	(91)
			NCT07031674	56	Completed	/	(92)
		pMN	NCT06614985	172	Not yet recruiting	Phase 2	(103)
	Atacicept	IgAN	NCT04716231	376	Active, not recruiting	Phase 3	(76)
			NCT02808429	16	Terminated(sponsor decision-unexpectedly slow enrollment)	Phase 2	(75)
		LN	NCT00573157	6	Terminated(due to unanticipated safety issues)	Phase 2/3	(93)
		pMN	NCT06983028	250	Recruiting	Phase 2	(104)
	Povetacicept	IgAN/pMN	NCT05732402	72	Active, not recruiting	Phase 1/2	(30)
		IgAN	NCT06564142	605	Active, not recruiting	Phase 3	(77)